Articles

Bacterial biosensors eavesdrop on the gut

Genetically engineered bacteria could help diagnose or monitor gut diseases.
Written byHannah Thomasy, PhD
| 11 min read
Florian Schmidt wears a white and green lab coat while working in a lab.

Florian Schmidt endows cells with the ability to store “memories” of gene expression in Randall Platt’s lab at the Swiss Federal Institute of Technology.

credit: Botnar Research Centre for Child Health

In 2009, artists Alexandra Daisy Ginsberg and James King teamed up with synthetic biology students at the University of Cambridge to create the Scatalogue. The students engineered E. coli to respond to a stimulus by changing color, creating a signal robust enough to be seen with the naked eye. The team envisioned a future in which these bacteria could detect problems in the gut, turning different colors to indicate different diseases; the artists brought the concept to life in the Scatalogue art project, a collection of cheerily colored (fake) feces to represent this hoped for advance in diagnostics.

Conditions in the gut are important for our overall health, yet historically, they have been very difficult to assess.
credit: istock/DrAfter123

While the Scatalogue isn’t yet a reality, it might not be far off. Advances in synthetic biology and expanded understanding of the gut microbiome enable researchers to create increasingly more sophisticated bacterial sensors that can recognize and record conditions in the complex environment of the human gut. While fecal analysis gives researchers a good idea of what’s happening at the far end of the gastrointestinal tract, it doesn’t necessarily indicate what’s happening in the several other feet of intestines between mouth and rectum (1).

Scientists hope that one day their genetically engineered bacterial systems will enable early diagnosis and continuous monitoring for gut conditions such as inflammatory bowel disease and cancer.

The first steps

Harvard University biologist Pamela Silver spent the first part of her career studying the movements of proteins and RNAs within cells; her early work formed the basis for a drug that is currently approved to treat some blood cancers. In the early 2000s, she was ready for a change. She linked up with the Synthetic Biology Working Group at the Massachusetts Institute of Technology (MIT) and decided to pivot her team to work in a new field.

She started thinking about engineering bacteria to sense specific things in their environments. Applying these biosensors in the gut, she said, “seemed kind of obvious. The gut is a key environment where bacteria live, including E. coli. One of the tenets of synthetic biology is that we know a whole lot about engineering certain organisms, and one of them is E. coli.”

The beauty of the lambda switch is that once it's on, it stably stays on.
- Pamela Silver, Harvard University

Bacteria evolved many ways to sense their environments; in one well characterized system, a specific promoter drives expression of a downstream gene in response to a drug called anhydrotetracycline. Silver decided to use this system in the first proof of concept study to create a bacterium able to sense conditions in the gut.

She didn’t only need the bacteria to respond to chemicals in the gut; she also needed them to “remember” the information. To endow the bacteria with memory, Silver borrowed a genetic switch from another model organism: bacteriophage lambda. The switch consists of two elements, cI and cro. Expression of one of these genes strongly represses transcription of the other, so the system is stable in the cI state (“off”) and in the cro state (“on”). “The beauty of the lambda switch is that once it's on, it stably stays on,” said Silver.

Silver engineered the bacteria so that the promoter would drive expression of cro, flipping the lamba switch to the cro, or “on,” state. She also added in a cro-driven reporter gene that would tell them when the switch had been flipped on.

To continue reading this article, subscribe for FREE toDrug Discovery News Logo

Subscribe today to keep up to date with the latest advancements and discoveries in drug development achieved by scientists in pharma, biotech, non-profit, academic, clinical, and government labs.

Add Drug Discovery News as a preferred source on Google

Add Drug Discovery News as a preferred Google source to see more of our trusted coverage.

About the Author

  • Hannah Thomasy

    Hannah joined Drug Discovery News as an assistant editor in 2022. She earned her PhD in neuroscience from the University of Washington in 2017 and completed the Dalla Lana Fellowship in Global Journalism in 2020. Her work has appeared in The New York Times, Undark, and New Scientist. She enjoys playing soccer and hiking and hopes to be a contestant on The Great Canadian Baking Show one day. 

    View Full Profile

Here are some related topics that may interest you:

Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Abstract illustration of colorful spectral emission peaks.
As flow cytometry panels grow larger and more complex, thoughtful panel design has become critical for experimental success.
A scientist in a white lab coat looking into a microscope in a brightly lit modern laboratory.
Learn how developmental and reproductive toxicology study selection supports regulatory decision-making and generates meaningful nonclinical safety data.
Illustration of multiple three-dimensional patient-derived organoids suspended against a dark blue background, representing tumor models used in precision oncology research.
By combining organoid biology with precision automation, researchers developed a miniaturized organoid screening platform that could help speed personalized cancer treatment testing.